Salute e Benessere

Novo Holdings to acquire majority stake in Single Use Support

Founded in 2017 in Kufstein, Austria by Johannes Kirchmair and Thomas Wurm, Single Use Support is at the forefront of transforming the production process for advanced pharmaceutical modalities with its equipment and consumables used in the bioprocessing value chain. With a focus on solutions for biological drug substances, cell and gene therapies, and mRNA vaccines, the company's customers include leading pharma companies, biotech companies and CDMOs. Founded in 2017 in Kufstein,Austriaby...
PR Newswire
15/05/2024

Groupe Casino: Termination of Trinity's temporary suspension of certain of its…

Termination of Trinity's temporary suspension of certain of its rights in Casino Paris, 15 May 2024Casino, Guichard-Perrachon (« Casino ») announces that it has been informed on 14 May 2024, of the decision of Trinity Investments Designated Activity Company, whose management company is Attestor Limited ("Trinity"), to end the temporary suspension of certain of its rights in Casino.It is recalled that in the context of Casino's financial restructuring, Mr. Thomas Doerane, observer...
Nasdaq GlobeNewswire
15/05/2024

Momcozy Successfully Concluded Mother's Day Campaign "Momcozy Village"…

Highlighting 'real connection,' Momcozy hosted significant events at Babylist Beverly Hills and engaging community get-togethers in La Jolla and Culver City. These gatherings exemplified the campaign's village concept, allowing mothers to physically connect, experience innovative Momcozy products firsthand, and share their motherhood journeys. Additionally, plans to extend these impactful events to more US cities further underscore Momcozy's dedication to enhancing maternal support nationwide…
PR Newswire
15/05/2024

Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational…

Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 Halle (Saale) / Munich, Germany, May 15, 2024- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its first quarter financial results for the...
Nasdaq GlobeNewswire
15/05/2024

Roche announces FDA approval of one of the first HPV self-collection solutions…

More than half of all U.S. cervical cancer patients are underscreened 1, which makes reducing barriers to sample collection and increasing access to screenings crucial to ultimately helping eliminate this deadly disease.Each year in the U.S., more than 13,000 patients are diagnosed with cervical cancer and approximately 4,000 die from this preventable disease, caused by HPV infection. 1 Roche's human papillomavirus (HPV) self-collection solution will improve access to testing...
Nasdaq GlobeNewswire
15/05/2024

Pharming Group announces the early redemption of the remaining outstanding €125…

THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE IMMEDIATELY FROM THEIR STOCKBROKER, SOLICITOR, ACCOUNTANT OR OTHER INDEPENDENT FINANCIAL OR LEGAL ADVISER. THIS NOTICE IS NOT FOR DISTRIBUTION IN OR TO ANY PERSON LOCATED IN ANY JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 15 May 2024:...
Nasdaq GlobeNewswire
15/05/2024

DSM B.V. publishes 2023 Annual Report

KPMG performed an audit of the financial statements. KPMG performed an audit of the financial statements. The full version of the 2023 annual report is available on the DSM website:https://www.dsm.com/corporate/investors/results-center/results-presentations.html#reports For more information Media enquiries: media@dsm-firmenich.comInvestor relations enquiries:investors@dsm-firmenich.com Forward-looking statementsThis press release may contain forward-looking statements...
PR Newswire
15/05/2024

Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024…

BioArctic's report for the first quarter 2024 will be published on May 17 at 08.00 a.m. CET. BioArctic's report for the first quarter 2024 will be published onMay 17at08.00 a.m. CET. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, onMay 15, 2024, at05.45 a.m. CET. For further...
PR Newswire
15/05/2024

AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid…

Previously, the Company had tested the AmacaGel platform without any active pharmaceutical agent. This trial will test the platform combined with a known anesthetic. The study will assess the tolerability, safety, pharmacokinetic and clinical activity of the AmacaGel platform with a known compound that has a long history of safety and efficacy. Previously, the Company had tested the AmacaGel platform without any active pharmaceutical agent. This trial will test the platform combined with a...
PR Newswire
15/05/2024

Eisai initiates rolling Biologics License Application to US FDA for Leqembi®…

Alzheimer's disease is an ongoing neurotoxic process that begins before and continues after amyloid-beta (Aβ) plaque deposition, which is a hallmark of the disease. Data suggests that early and continued treatment may prolong the benefit even after Aβ plaque is cleared from the brain. If approved by the FDA, patients who have completed the biweekly IV initiation phase could transfer to the subcutaneous autoinjector 360 mg weekly maintenance regimen, currently under review. This would maintain…
PR Newswire
15/05/2024

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI®…

TOKYO and CAMBRIDGE, Mass., May14, 2024(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI ® ) subcutaneous autoinjector for weekly...
Nasdaq GlobeNewswire
15/05/2024

ONWARD® Medical Schedules Webcast to Provide Q1 2024 Business Update

The webcast will be held on May 23, 2024, at 2:30PM CET / 08:30AM ET. It will be hosted by CEO Dave Marver who will discuss highlights from Q1 2024 and provide a business update.To join the webcast via Zoom, please register usingthis link.Participants may also join by phone:+32 2 290 9360 (Belgium)+49 69 3807 9884 (Germany)+31 20 794 0854 (Netherlands)+41 22 591 0156 (Switzerland)+44 203 481 5240 (United Kingdom)+1 346 248 7799 (US) Additional telephone numbers...
Nasdaq GlobeNewswire
15/05/2024

ESOC 2024: Higher income reduces stroke mortality risk by a third, new study…

As well as identifying a significant connection between income, education level and post-stroke mortality risk, the study uncovered a concerning trend regarding the cumulative impact of SDoH factors. Patients with one unfavourable factor faced an 18% higher risk of mortality compared to patients without any unfavourable factors. This risk escalated to 24% for patients with two to four unfavourable factors. As well as identifying a significant connection between income, education level and...
PR Newswire
15/05/2024

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study…

PARIS and CAMBRIDGE, Mass., May14, 2024(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the U.S. Food and Drug Administration (“US FDA”) issued a Study May Proceed Letter for a randomized Phase 2 study evaluating NBTXR3 for the treatment of patients...
Nasdaq GlobeNewswire
14/05/2024

GENFIT Reports First Quarter 2024 Financial Information

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2024-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2024 and revenues for the first three months of 2024. 1Cash position As of March 31, 2024, the Company's cash and cash equivalents amounted to €74.0 million compared with €128...
Nasdaq GlobeNewswire
14/05/2024

Nyxoah Reports First Quarter 2024 Financial and Operating Results

REGULATED INFORMATIONNyxoah Reports First Quarter 2024 Financial and Operating Results Announced DREAM U.S. pivotal study achieved primary endpointsOn track for FDA approval as early as end of 2024Mont-Saint-Guibert, Belgium – May 14, 2024 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA),...
Nasdaq GlobeNewswire
14/05/2024

Air Shower Market to Hit $7.30 Billion by 2029 - Market Soars as Contamination…

Browse in-depth TOC on the Air Shower Market103 – Tables86 – Figures 287 – Pages Browse in-depth TOC on the Air Shower Market103 – Tables 86 – Figures 287 – Pages The Global Air Shower Market Report Scope Watch Out for How the Electronics & Semiconductor Industry Creating Market Opportunities The growth of the fabrication industry, which encompasses manufacturing products like electronics inTaiwanandSoutheast Asia, has accelerated the development...
PR Newswire
14/05/2024

The Department of Health, Abu Dhabi and PHSSR join hands to launch the region's…

The report's findings delve intoAbu Dhabi'shealth ecosystem through seven key themes: governance, financing, healthcare workforce, medicine and technology, service delivery, population health and environmental sustainability. Under each domain, the report identifies the unique strengths ofAbu Dhabi'shealthcare system, and areas of focus with recommendations to bolster the system's sustainability and resilience. While launching the report, H.E. Dr.Ahmed AlKhazraji, Acting...
PR Newswire
14/05/2024

Information on the Total Number of Voting Rights (Denominator) following…

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion...
Nasdaq GlobeNewswire
14/05/2024

Blood Culture Tests Market Anticipated to Reach New Heights - the Market to…

Browse In-depth TOC on the Blood Culture Tests Market Browse In-depth TOC on the Blood Culture Tests Market 314 – Pages 123 - Tables 132 - Figures Blood Culture Tests Market Report Scope The growing burden of infectious diseases associated with the bloodstream is a major factor fueling the demand for blood culture tests. The increasing demand for blood culture testing, which results in growing research across the sector, delivers new pathways...
PR Newswire
14/05/2024

Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast…

Idorsia will publish its Full Year 2023 and Q1 2024 Financial Reporting on Tuesday May 21, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same day.Date: Tuesday, May 21, 2024 Time: 14:00 CEST / 11:00 BST / 08:00 EDT The call will start with presentations by senior management, followed by a Q&A session. Dial-inprocedure: 1) Participants are required to register in advance of the conference (link...
Nasdaq GlobeNewswire
14/05/2024

Bulletin from Sobi's Annual General Meeting (AGM)

The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits. The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits. The Board members and the chief executive officer were discharged from liability for the financial year 2023. Election of Board of Directors, remuneration to the Directors, election of Auditor and remuneration to the Auditor The...
PR Newswire
14/05/2024

Notification of managers' transactions

ANNOUNCEMENT NO. 265 Notification of managers' transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of member of the Board of Directors Peter Reich in the attached PDF document.For further information, please contact:...
Nasdaq GlobeNewswire
14/05/2024

Oxehealth Granted Regulatory Clearances for Mental Health Sleep Monitoring

Given the proven links between sleep and mental health, sleep insights should be a key part of providing the best care and treatment. But until now, obtaining objective and accurate sleep data in acute mental health has been a challenge. Given the proven links between sleep and mental health, sleep insights should be a key part of providing the best care and treatment. But until now, obtaining objective and accurate sleep data in acute mental health has been a challenge. "In inpatient...
PR Newswire
14/05/2024
Altri  Comunicati